OOIR: Observatory of International Research

Papers

(The H4-Index of Antiviral Research is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination	105
Editorial Board	90
A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN	71
Editorial Board	68
Editorial Board	65
Inhibition of p38 signaling curtails the SARS-CoV-2 induced inflammatory response but retains the IFN-dependent antiviral defense of the lung epithelial barrier	54
Co-delivery of Cas9 mRNA and guide RNAs edits hepatitis B virus episomal and integration DNA in mouse and tree shrew models	49
Long-term and efficient inhibition of hepatitis B virus replication by AAV8-delivered artificial microRNAs	47
Corrigendum to “Crystal structure and cap binding analysis of the methyltransferase of langat virus” [Antivir. Res. 208 (2022) 105459]	47
Novel inhibitors of HSV-1 protease effective in vitro and in vivo	44
Editorial Board	43
Progress in novel delivery technologies to improve efficacy of therapeutic antibodies	40
Hepatitis C virus elimination: So close, so far?	40
Assessment of the broad-spectrum host targeting antiviral efficacy of halofuginone hydrobromide in human airway, intestinal and brain organotypic models.	39
Targeted inhibition of IGF2BP1 effectively suppresses HBV replication via an m6A-dependent manner	38
Berberine promotes K48-linked polyubiquitination of HNF4α, leading to the inhibition of HBV replication	38
Development of MDCK-based quadrivalent split seasonal influenza virus vaccine with high safety and immunoprotection: A preclinical study	38
Methyl rosmarinate is an allosteric inhibitor of SARS-CoV-2 3 CL protease as a potential candidate against SARS-cov-2 infection	37
Ligand-based design of peptide entry inhibitors targeting the endosomal receptor binding site of filoviruses	37
Long-term effects of peginterferon-based therapy versus nucleos(t)ide analogue monotherapy in non-cirrhotic HBeAg-positive chronic hepatitis B patients	36
The prophylactic and therapeutic efficacy of the broadly active antiviral ribonucleoside N-Hydroxycytidine (EIDD-1931) in a mouse model of lethal Ebola virus infection	36
Discovery and development of INNA-051, a TLR2/6 agonist for the prevention of complications resulting from viral respiratory infections	36
Chemical-induced degradation of PreS2 mutant surface antigen via the induction of microautophagy	36
Editorial Board	35
Conserved use of the sodium/bile acid cotransporter (NTCP) as an entry receptor by hepatitis B virus and domestic cat hepadnavirus	34

A novel high-throughput single B-cell cloning platform for isolation and characterization of high-affinity and potent SARS-CoV-2 neutralizing antibodies	31
Novel strategy for Poxviridae prevention: Thermostable combined subunit vaccine patch with intense immune response	31
Assessment of repurposed compounds against coronaviruses highlights the antiviral broad-spectrum activity of host-targeting iminosugars and confirms the activity of potent directly acting antivirals	30
JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase	29